AC Immune ACIU
NASDAQ ACIU
$2.46 -0.03 (-1.19%)
As of: Oct 21, 2026 · 9:36 AM EDT

AC Immune (ACIU) Convertible Debt (2019)

Updated

AC Immune (ACIU) reported Convertible Debt of $46.93 million for the quarter ended Mar 31, 2019.

Analysis

AC Immune (ACIU) Convertible Debt (2019) Analysis & Trends

As of Dec 31, 2016, AC Immune posted Convertible Debt of $9.55 million, up 51.6% from the prior year.

  • By year, Convertible Debt came in at $6.3 million in the year ended Dec 31, 2015.
  • The figure for the quarter ended Mar 31, 2019 ranks as the lowest quarterly Convertible Debt since the quarter ended Dec 31, 2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.84 Bn 1,106.42 Bn 19.71 Bn
2 Johnson & Johnson 618.03 Bn 536.55 Bn 17.26 Bn
3 AbbVie 507.69 Bn 480.80 Bn 12.70 Bn
4 Merck 366.91 Bn 321.28 Bn 12.21 Bn
5 Novartis Ag 298.54 Bn 262.53 Bn 11.24 Bn
6 Astrazeneca 263.16 Bn 236.84 Bn 12.86 Bn
7 Amgen 236.31 Bn 191.71 Bn 7.24 Bn
8 Gilead Sciences 192.91 Bn 167.11 Bn 6.22 Bn
9 Pfizer 171.40 Bn 118.04 Bn 10.94 Bn
10 AC Immune 247.85 Mn -190.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 46.98 Mn
API Access

AC Immune Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ACIU&period=max&api_key=YOUR_API_KEY